

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE I/IIa CLINICAL TRIAL OF JAB-BX102 FOR THE TREATMENT OF ADVANCED SOLID TUMOR IN CHINA

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**” or “**Jacobio**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that, on September 1, 2022, the Group has completed the first patient dosage in Phase I/IIa clinical trial of an in-house R&D drug candidate CD73 monoclonal antibody, JAB-BX102, for the treatment of advanced solid tumor.

JAB-BX102 is Jacobio’s first big molecule program entered into the clinical stage. This is a Phase I/IIa multi-center, open-label clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of anti-tumor activity of JAB-BX102 monotherapy and combination with Pembrolizumab in adult patients with advanced solid tumors.

JAB-BX102 is a humanized monoclonal antibody against CD73. CD73 is a protein that plays a key role in the adenosine pathway, and its inhibition has broad therapeutic potential for tumors that are reliant on an active adenosine pathway. Combination treatment of JAB-BX102 with immune checkpoint drugs such as PD-(L)1 (anti-PD-1, or anti-PD-L1) antibodies can result in synergistic anti-tumor efficacy. Currently, there is no anti-CD73 antibodies similar products that is successfully developed, approved and commercialized for cancer therapy in the global market. Preclinical data have shown that JAB-BX102 has the advantage of dose activity and has the potential to benefit patients with solid tumors.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that JAB-BX102 will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board of Directors
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, September 2, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG, Dr. Dong LYU and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Daqing CAI and Dr. Ge WU as independent non-executive Directors.